1. Comparison of the effectiveness of intravenous streptokinase versus recombinant tissue type plasminogen activator in patients with acute myocardial infarction. (Sub-investigator, 1990)
2. Effectiveness of Tranpro® (Tranilast) on Restenosis after Percutaneous Transluminal Coronary Angioplasty (principal investigator, 2000)
3. An Open, Randomized, Comparative Evaluation of Performance and Safety of Cypher Sirolimus-Eluting Stent (Sirolimus Coated Modified Bx VELOCITY Balloon-Expandable Stent) in the Treatment of Patients with de novo or Restenotic Native Coronary Artery Lesions versus uncoated Bx VELOCITY Balloon-Expandable Stent (principal investigator, 2003)
4. TAXUS ATLAS trial: A multi-center, single-arm study of the TAXUS Liberté-SR stent for the treatment of patients with de novo coronary Artery lesionS (principal investigator, 2005)
5. ROCKET-AF: A prospective, randomized, double-blind, double-dummy, parallel-Group, multicenter, Event-Driven, non-inferiority study comparing the efficacy and safety of once-daily oral rivaroxaban (Bay 59-7939) with adjusted-dose oral warfarin for the prevention of stroke and non-central nervous system systemic embolism in subjects with non-valvular atrial fibrillation (National principal investigator, 2007)
6. ISIS 301012-CS5: A RAndomized , Double-blind, placebo-controlled study to assess the safety and efficacy of ISIS 301012 as add-on therapy in homozygous familial hyperCHOLesterolemia subjects (principal investigator, 2008)
7. ISIS 301012-CS6：An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of ISIS 301012 in Subjects with Familial Hypercholesterolemia (principal investigator, 2008)
8. TRACER, 2009: A multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of SCH 530348 in addition to standard of care in subjects with acute coronary syndrome. (principal investigator, 2009)
9. IMPROVE IT, 2009: A multicenter, double-blind, randomized study to establish the clinical benefit and safety of vytorin vs simvastatin monotherapy in high-risk subjects presenting with acute coronary syndrome. (principal investigator, 2009)
10. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of Two Different Regimens of Mipomersen in Patients with Familial Hypercholesterolemia and Inadequately Controlled Low-Density Lipoprotein Cholesterol (National lead Investigator, 2012)
11. FOURIER, 2013:A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When AMG 145 is Used in Combination With Statin Therapy in Patients with Clinically Evident Cardiovascular Disease. (AMG 145 20110118 – FOURIER Trial) (National lead Investigator, 2013)
12. A Randomized, Multi-Center, Placebo-Controlled, Parallel Group Study to Determine the Effects of AMG 145 Treatment on Atherosclerotic Disease Burden As Measured By Intravascular Ultrasound in Subjects Undergoing Coronary Catheterization (National lead Investigator, 2013)
13. A Randomized, Double-blind, Placebo-controlled, Multi-center, Cross-over Study of Rosuvastatin in Children and Adolescents (aged 6 to <18 years) with Homozygous Familial Hypercholesterolemia (HoFH) (National lead Investigator, 2014)
14. LOWER:Lomitapide Observational Worldwide Evaluation Registry (National lead Investigator, 2014)
15. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Alirocumab in patients with Homozygous Familial Hypercholesterolemia. (08-Dec-2017, R727-CL-1628, ICON, National lead Investigator)
16. A Randomized Double-Blind Placebo-controlled Study Followed by an Open Label Treatment Period to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents with Heterozygous Familial Hypercholesterolemia. (27 Oct 2017, EFC14643, Sanofi, National lead Investigator)
17. An Open-Label Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents with Homozygous Familial Hypercholesterolemia. (16 Mar 2018, EFC14660, Sanofi, national lead Investigator)
18. Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel Group Study to Characterize the Efficacy, Safety, and Tolerability of 24 Weeks of Evolocumab for Low Density Lipoprotein-cholesterol (LDL-C) Reduction, as Add-on to Diet and Lipid-lowering Therapy, in Pediatric Subjects 10 to 17 Years of Age with Heterozygous Familial Hypercholesterolemia (HeFH) (Amgen, Protocol Number: 20120123)
19. An Open-label, Single-arm, Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of Evolocumab for LDL-C Reduction, as Add-on to Diet and Lipid-lowering Therapy, in Pediatric Subjects From 10 to 17 Years of Age With Heterozygous Familial Hypercholesterolemia (HeFH) or Homozygous Familial Hypercholesterolemia (HoFH) (Amgen, Protocol Number: 20120124)
20. ORION-5 Study: A Two-Part (Double-Blind Placebo-Controlled/Open-Label) Multicenter Study To Evaluate Safety, Tolerability, And Efficacy Of Inclisiran In Subjects With Homozygous Familial Hypercholesterolemia (HoFH) (The Medicines company)
21. VESALIS-CV Study: A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke (Amgen Protocol Number: 20170625, 2019, Site Number: 61002)
22. ORION-16 Study: Two part (double-blind inclisiran versus placebo [Year 1] followed by open-label inclisiran [Year 2]) randomized multicenter study to evaluate safety, tolerability, and efficacy of inclisiran in adolescents (12 to less than 18 years) with heterozygous familial hypercholesterolemia and elevated LDL-cholesterol (ORION-16)
23. Description of evolocumab use among adults with established atherosclerotic cardiovascular disease or hypercholesterolemia in Asia-Pacific region – an observational study of clinical practice. (Amgen, Protocol Number: 20190330)